Source comparison
CJC-1295 No DAC & Ipamorelin Study — Comparison Table
Peak GH Increase (× Baseline) 1.6–2.1× 1.8–2.3× 2.8–3.4× Synergistic amplification. Combined effect exceeds additive sum Mechanism of Action GHRH receptor agonist (cAMP pathway) Ghrelin receptor agonist (PLC pathway) Dual-pathway activation (cAMP + PLC converg
This comparison does not assign a generated winner or score.
- Peak GH Increase (× Baseline)
- 1.6–2.1×
- 1.8–2.3×
- 2.8–3.4×
- Synergistic amplification. Combined effect exceeds additive sum
- Mechanism of Action
- GHRH receptor agonist (cAMP pathway)
- Ghrelin receptor agonist (PLC pathway)
- Dual-pathway activation (cAMP + PLC convergence)
- Independent receptor pathways produce non-redundant effects
- Plasma Half-Life
- ~30 minutes
- ~2 hours
- N/A (pharmacokinetics unchanged in combination)
- Both clear rapidly. Preserves natural pulsatility
- Cortisol Elevation
- Minimal (<5% above baseline)
- Minimal (<8% above baseline)
- 8–12% above baseline (not statistically significant)
- Combination maintains cortisol selectivity
- Prolactin Elevation
- None documented
- Minimal (Ipamorelin is selective)
- Minimal (<10% above baseline)
- No prolactin desensitization with chronic use
- Standard Research Dose
- 100 mcg per injection
- 100–200 mcg per injection
- 100 mcg CJC + 100–200 mcg Ipamorelin
- 1:1 or 1:2 ratio most common in studies
- Peak Plasma Time
- 20–30 minutes post-injection
- 20–30 minutes (synchronized)
- Aligned kinetics maximize receptor co-activation
- IGF-1 Increase (4–6 weeks)
- 18–25% above baseline
- 15–22% above baseline
- 25–35% above baseline
- Sustained GH elevation translates to hepatic IGF-1 production
- Bottom Line
- Effective single-agent protocol
- Superior synergistic effect for research applications requiring maximal GH pulse amplitude without hormonal side effects
- Combination protocols are the standard in modern secretagogue research